Complete dopamine D2 receptor occupancy without extrapyramidal side effects under benperidol.
Schönfeldt-Lecuona
Carlos
C
Juengling
Freimut D
FD
Connemann
Bernhard J
BJ
Reske
Sven N
SN
Spitzer
Manfred
M
Kassubek
Jan
J
D000328:Adult; D001479:Basal Ganglia / Q000000981:diagnostic imaging / Q000187:drug effects / Q000503:physiopathology; D001544:Benperidol / Q000097:blood / Q000494:pharmacology / Q000627:therapeutic use*; D002250:Carbon Radioisotopes; D003024:Clozapine / Q000097:blood / Q000494:pharmacology / Q000627:therapeutic use; D004295:Dihydroxyphenylalanine / Q000031:analogs & derivatives*; D004409:Dyskinesia, Drug-Induced / Q000503:physiopathology / Q000517:prevention & control*; D005462:Fluorine Radioisotopes; D006801:Humans; D008297:Male; D020891:Raclopride / Q000493:pharmacokinetics; D017448:Receptors, Dopamine D2 / Q000187:drug effects* / Q000378:metabolism; D012559:Schizophrenia / Q000188:drug therapy; D014055:Tomography, Emission-Computed / Q000379:methods; D016896:Treatment Outcome; D014463:Ultrasonography
D002250:Carbon Radioisotopes; D005462:Fluorine Radioisotopes; D017448:Receptors, Dopamine D2; C043437:fluorodopa F 18; D020891:Raclopride; D004295:Dihydroxyphenylalanine; D001544:Benperidol; D003024:Clozapine